Carrington Donates Medical Supplies to Hurricane Victims Through Congressman Pete Sessions' Initiative

Carrington Donates Medical Supplies to Hurricane Victims Through Congressman Pete Sessions' Initiative

Special Program Developed for Additional Requests for Aid

IRVING, Texas, Sept. 2 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (NASDAQ:CARN) today announced it has donated medical supplies in support of Congressman Pete Sessions' (R-TX 32nd) initiative to provide immediate aid to the hurricane victims of the Gulf Coast. Carrington also initiated a special program for individuals and health professionals to send requests for additional assistance or follow up for medical supplies.

A special phone number has been designated for Carrington's special relief program. Individuals and professionals may call 800-471-8817 and ask for "Sheri." The designated customer service representative will assist them in acquiring medical supplies and in expediting shipment.

Medical supplies left Carrington on Wednesday evening, August 31 and arrived in Jackson, Mississippi for distribution on Thursday, September 1. Included in the donation were Carrington-branded wound gels, films, cleansers, odor eliminators, etc. The products are some of Carrington's most effective wound and skin care products used in hospitals, medical centers, nursing homes and home health care centers in the U.S. and internationally.

Previously, Carrington had donated products in the U.S. and around the world for countries including Costa Rica, Honduras, Venezuela, Guatemala, Russia, Africa, China, Vietnam and Tsunami-affected countries. Over the years, the Company has donated millions of dollars in product to various relief programs.

Carlton Turner, CEO, stated, "With family and friends in Mississippi, Alabama and New Orleans, this disaster carries a personal and family connection. Naturally, I am delighted with the leadership position Congressman Sessions has taken. Additionally, having gone through Hurricane Camille's devastation of the Mississippi Gulf Coast in 1969 and having lost all personal belongings in a tornado in 1971, I not only relate to my family's loss, but also know firsthand the pain and suffering being experienced by the victims of this natural disaster."

Turner continued, "In a time of urgent need for victims in our own country, Carrington is proud to be a part of numerous efforts in aiding our neighbors in the affected states. Our employees are collecting cash and items for the Irving Chamber of Commerce program, as well as participating in other community fund raisers."

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products under the AloeCeuticals(R) brand and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. The Company's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products are honored with the internationally coveted CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com/ .

Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-Q, filed August 15, 2005.

Source: Carrington Laboratories, Inc.

CONTACT: Carlton E. Turner, Chief Executive Officer of Carrington
Laboratories, Inc., +1-972-518-1300, or +1-800-527-5216

Web site: http://www.carringtonlabs.com/

-------
Profile: jene29